DIA Biosimilars 2013

Hesperion

Averion Restructures as Revenues Dip

Friday, August 21, 2009 06:32 AM

Southborough, Mass.-based contract research organization (CRO) Averion is restructuring its senior management team in an effort to grow its services and improve its bottom line.

More... »

Cenduit: Now with Patient Reminders

Averion’s 2008 Revenues Up 90%, Net Loss Increases by $33.5M

Thursday, April 2, 2009 08:00 AM

Full-year 2008 revenues for oncology CRO Averion increased 90% over 2007, thanks in large part to an increase in European activity and the October 2007 acquisition of Hesperion, a clinical research organization based in Switzerland. Net service revenues in 2008 were $66.4 million, compared with $34.9 million in 2007.

More... »

CRF Health – eCOA Forum

Averion Revenues Double Following Hesperion Acquisition

Tuesday, November 18, 2008 12:22 PM

Averion, a contract research organization (CRO) specializing in oncology, reported its third quarter revenues more than doubled following its acquisition of Swiss CRO Hesperion.

More... »

Top Stories for the Week of Sept. 11th 2006

Tuesday, September 12, 2006 04:19 PM

Top News

Hesperion Acquires TouchStone Research in Maryland

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs